$NURO
NeuroMetrix, Inc. Stock $nuro

$nuro Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000162828024023431 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$769.1K	$1.094M
YoY Change	-53.55%	-36.6%
Cost Of Revenue	$277.2K	$576.5K
YoY Change	-48.33%	9.53%
Gross Profit	$491.9K	$517.0K
YoY Change	-56.05%	-56.86%
Gross Profit Margin	63.96%	47.28%
Selling, General & Admin	$2.054M	$2.827M
YoY Change	3.24%	27.99%
% of Gross Profit	417.48%	546.88%
Research & Development	$266.9K	$943.6K
YoY Change	-64.57%	34.9%
% of Gross Profit	54.26%	182.5%
Depreciation & Amortization	$24.91K	$24.91K
YoY Change	143.74%	143.67%
% of Gross Profit	5.06%	4.82%
Operating Expenses	$2.321M	$3.771M
YoY Change	-15.39%	29.66%
Operating Profit	-$1.829M	-$3.254M
YoY Change	12.64%	90.28%
Interest Expense	$13.01K	$19.16K
YoY Change
% of Operating Profit
Other Income/Expense, Net	$340.7K	$224.4K
YoY Change	294.22%	65.13%
Pretax Income	-$1.488M	-$3.030M
YoY Change	-3.19%	92.46%
Income Tax
% Of Pretax Income
Net Earnings	-$1.488M	-$3.030M
YoY Change	-3.19%	92.45%
Net Earnings / Revenue	-193.45%	-277.04%
Basic Earnings Per Share	-$0.74	-$1.67
Diluted Earnings Per Share	-$0.74	-$1.67
COMMON SHARES
Basic Shares Outstanding	2.011M shares	1.987M shares
Diluted Shares Outstanding	2.001M shares	1.812M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.43M	$17.60M
YoY Change	-16.29%	-13.11%
Cash & Equivalents	$1.607M	$1.260M
Short-Term Investments	$14.82M	$16.34M
Other Short-Term Assets	$315.7K	$611.7K
YoY Change	-4.78%	20.33%
Inventory	$1.450M	$1.471M
Prepaid Expenses
Receivables	$280.6K	$469.7K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$18.48M	$20.15M
YoY Change	-17.11%	-12.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$243.6K	$268.5K
YoY Change	-46.77%	72.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$26.40K	$26.40K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$453.2K	$512.2K
YoY Change	-6.38%	-2.23%
TOTAL ASSETS
Total Short-Term Assets	$18.48M	$20.15M
Total Long-Term Assets	$453.2K	$512.2K
Total Assets	$18.93M	$20.66M
YoY Change	-16.88%	-12.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$314.0K	$144.6K
YoY Change	73.04%	-63.89%
Accrued Expenses	$1.127M	$1.554M
YoY Change	9.62%	79.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.590M	$1.847M
YoY Change	31.39%	30.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$28.21K	$60.95K
YoY Change	-81.46%	-66.2%
Total Long-Term Liabilities	$28.21K	$60.95K
YoY Change	-81.46%	-66.2%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.590M	$1.847M
Total Long-Term Liabilities	$28.21K	$60.95K
Total Liabilities	$1.618M	$1.908M
YoY Change	18.79%	19.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$214.6M	-$213.1M
YoY Change	3.84%	3.89%
Common Stock	$202.00	$199.00
YoY Change	-76.46%	-74.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.31M	$18.76M
YoY Change
Total Liabilities & Shareholders Equity	$18.93M	$20.66M
YoY Change	-16.88%	-12.48%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$1.488M	-$3.030M
YoY Change	-3.19%	92.45%
Depreciation, Depletion And Amortization	$24.91K	$24.91K
YoY Change	143.74%	143.67%
Cash From Operating Activities	-$1.364M	-$2.081M
YoY Change	-5.97%	85.6%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$1.709M	$138.3K
YoY Change	620.24%	-116.52%
Cash From Investing Activities	$1.709M	$138.3K
YoY Change	620.24%	-116.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.600K	$1.471M
YoY Change	-99.63%
NET CHANGE
Cash From Operating Activities	-1.364M	-$2.081M
Cash From Investing Activities	1.709M	$138.3K
Cash From Financing Activities	2.600K	$1.471M
Net Change In Cash	347.0K	-$472.0K
YoY Change	-167.56%	-75.9%
FREE CASH FLOW
Cash From Operating Activities	-$1.364M	-$2.081M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-70490	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	32217	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	338326	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1121417	usd
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-836984	usd
CY2023Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1958401	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4335020	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1259930	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2376619	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	212261	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	576539	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	526372	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	517017	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	1198399	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	943552	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	699425	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1061729	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	815872	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1765727	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1393171	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	3771008	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	196548	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-108661	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-78467	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2908468	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3253991	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1710069	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	19162	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	135895	usd
CY2024Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	205255	usd
CY2023Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	224417	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	135895	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3029574	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1574174	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.67
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.67
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.64
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.64
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1812455	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1812455	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	961153	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	961153	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3029574	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1574174	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	212261	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	65874	usd
CY2024Q1	nuro	Other Comprehensive Income Realized Gain Adjustment OtherComprehensiveIncomeRealizedGainAdjustment	205255	usd
CY2023Q1	nuro	Other Comprehensive Income Realized Gain Adjustment OtherComprehensiveIncomeRealizedGainAdjustment	0	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3022568	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1508300	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	20091317	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	216164	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1471099	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2024Q1	nuro	Other Comprehensive Income Realized Gain Adjustment OtherComprehensiveIncomeRealizedGainAdjustment	205255	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	18756012	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	23355687	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	165361	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	65874	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1574174	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	22012748	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-3029574	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-1574174	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24908	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10222	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	216164	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	165361	usd
CY2024Q1	nuro	Inventory Charge Cost Of Revenues InventoryChargeCostOfRevenues	74209	usd
CY2023Q1	nuro	Inventory Charge Cost Of Revenues InventoryChargeCostOfRevenues	63420	usd
CY2024Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	0	usd
CY2023Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	109198	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	205255	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-49174	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-13781	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-70956	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	737487	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2081401	usd
CY2024Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	7361714	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	9336984	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	7500000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	8500000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	138286	usd
CY2024Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1471099	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1471099	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-472016	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1731946	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	17600000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	25000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	25000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	961153	shares
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	378237	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	408047	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.</span></div>
CY2024Q1	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	7006	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3029574	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	65874	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-3029574	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1574174	usd
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1812455	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.67
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.67
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.64
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.64
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	115529	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	98913	shares
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	16092003	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	248164	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	987	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	16339180	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	16025034	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	240171	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	16265205	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	17594916	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	17549495	usd
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1093201	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1151381	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1471438	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1559428	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	547498	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	298534	usd
CY2024Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	202424	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	346245	usd
CY2024Q1	us-gaap	Restructuring Reserve RestructuringReserve	555000	usd
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	usd
CY2024Q1	nuro	Accrued Clinical Current AccruedClinicalCurrent	37383	usd
CY2023Q4	nuro	Accrued Clinical Current AccruedClinicalCurrent	39000	usd
CY2024Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	8000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	9400	usd
CY2024Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	143185	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	141672	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	60736	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	41888	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1554226	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	876739	usd
CY2024Q1	us-gaap	Severance Costs1 SeveranceCosts1	580427	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	124339	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	117431	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	241770	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.15
CY2024Q1	nuro	Operating Lease Discount OperatingLeaseDiscount	32433	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	148391	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	60946	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	241770	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	50377	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	49232	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M
CY2024Q1	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	10
CY2024Q1	us-gaap	Severance Costs1 SeveranceCosts1	580427	usd

Files In Submission

Name	View Source	Status
0001628280-24-023431-index-headers.html	Edgar Link	pending
0001628280-24-023431-index.html	Edgar Link	pending
0001628280-24-023431.txt	Edgar Link	pending
0001628280-24-023431-xbrl.zip	Edgar Link	pending
a10q33124exhibit311.htm	Edgar Link	pending
a10q33124exhibit312.htm	Edgar Link	pending
a10q33124exhibit32.htm	Edgar Link	pending
exhibit102-sngemploymentag.htm	Edgar Link	pending
exhibit103-tthemploymentag.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nuro-20240331.htm	Edgar Link	pending
nuro-20240331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
nuro-20240331_lab.xml	Edgar Link	unprocessable
nuro-20240331_pre.xml	Edgar Link	unprocessable
nuro-20240331_htm.xml	Edgar Link	completed
nuro-20240331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
nuro-20240331_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NURO
NeuroMetrix, Inc. Stock $nuro

2024 Q2 Form 10-Q Financial Statement

#000162828024023431 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NURO NeuroMetrix, Inc. Stock $nuro

2024 Q2 Form 10-Q Financial Statement

#000162828024023431 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NURO
NeuroMetrix, Inc. Stock $nuro